BeiGene to acquire global license to Ensem Therapeutics' CDK

BeiGene has signed an agreement to acquire an exclusive worldwide license to Ensem Therapeutics’ cyclin-dependent kinase 2 (CDK2) inhibitor.

Related Keywords

Shengfang Jin , Lai Wang , , Kinetic Ensemble ,